歌禮製藥(01672.HK)就新冠藥物簽訂內地利托那韋授權與供應協議
歌禮製藥-B(01672.HK)公布,其全資附屬公司歌禮藥業(浙江)已與輝瑞中國就新冠藥物PAXLOVID簽訂中國大陸利托那韋授權與供應協議。
根據協議,歌禮將非排他性地授權輝瑞中國在中國大陸使用歌禮的利托那韋片部分註冊資料用於新冠藥物PAXLOVID,並為輝瑞中國在中國大陸生產和供應利托那韋片。協議自簽署之日起生效,有效期為5年。該產品實際供應量取決於協議期內輝瑞中國的實際採購訂單。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.